Bio-Rad Laboratories, Inc. Class A (BIO)

293.49
0.64 0.22
NYSE
Prev Close 294.13
Open 293.49
Day Low/High 292.47 / 297.43
52 Wk Low/High 220.05 / 345.15
Volume 156.02K
Exchange NYSE
Shares Outstanding 29.80B
Market Cap 8.77B
Div & Yield N.A. (N.A)
8 Health Care Stocks to Buy

8 Health Care Stocks to Buy

HCA Holdings, Thermo Fisher and Covidien are defensive bets to beat market volatility, according to analysts.

BioAlliance Pharma Announces 2 Key Decisions

BioAlliance Pharma Announces 2 Key Decisions

Regulatory News: BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to specialty and orphan oncology products, today announces: Following PAR Strativa restructuring and...

10 Health Care Stocks to Watch

10 Health Care Stocks to Watch

These defensive stocks have outperformed their peers and show potential upside.

Bio-Rad Laboratories' CEO Discusses Q2 2011 Results - Earnings Call Transcript

Bio-Rad Laboratories' CEO Discusses Q2 2011 Results - Earnings Call Transcript

Bio-Rad Laboratories' CEO Discusses Q2 2011 Results - Earnings Call Transcript

Bio-Rad Stock Hits New 52-Week High (BIO)

Bio-Rad Stock Hits New 52-Week High (BIO)

Bio-Rad Laboratories (NYSE:BIO) hit a new 52-week high Friday as it is currently trading at $126.15, above its previous 52-week high of $125.43 with 67,867 shares traded as of 12:11 p.m. ET. Average volume has been 70,000 shares over the past 30 days.

HCA, Eaton, Cabot: Analysts' New Ratings

HCA, Eaton, Cabot: Analysts' New Ratings

HCA coverage started at several firms with buy and outperform ratings. Cabot downgraded at Stifel from Buy to Hold. Eaton upgraded at Oppenheimer.

Bio-Rad Reaches New 52-Week High (BIO)

Bio-Rad Reaches New 52-Week High (BIO)

Bio-Rad Laboratories (NYSE:BIO) hit a new 52-week high Monday as it is currently trading at $125.22, above its previous 52-week high of $125.01 with 61,047 shares traded as of 2:36 p.m. ET. Average volume has been 69,300 shares over the past 30 days.

Google: Analysts' New Targets, Estimates

Google: Analysts' New Targets, Estimates

Google estimates, target raised at Morgan Stanley. Shares of GOOG now seen reaching $730.

QLogic: Analysts' Upgrades, Downgrades

QLogic: Analysts' Upgrades, Downgrades

QLogic downgraded at Morgan Stanley from Overweight to Equal-weight. Company is facing lower server demand.

AutoNavi's IPO, Financially Stupid People

Gregg Greenberg breaks down today's market action with guests Catherine Zhang, CFO of AutoNavi, and Jason Kelly, author of "Financially Stupid People Are Everywhere".

STOCK PICKS: Top 5 Fast-Growth for Oct. 20

ManTech, FTI Consulting, Amdisys, Neogen and Bio-Rad make the list.

Make Money From 'Baby Boomer' Stocks

These names offer ways to play off the aging demographic.

Top Explosive Short-Squeeze Stocks

These 10 heavily shorted stocks could surge on any positive catalyst.

IRA Investing: Mid-Term Still Looks Bullish

The CBOE Put/Call Ratio points to an upward market direction, so portion cash appropriately.

Friday's Health Winners & Losers

Pfizer edges lower.

Ciphergen Sets Unit Sale

The business will be sold to Bio-Rad Laboratories.

Bio-Rad Testing Buy

Bio-Rad Testing Buy

It acquires Blackhawk.

Health Stocks in Motion

Impax Labs falls 23%.

Health Stocks in Motion

LanVision surges on an IBM partnership.

Health Stocks in Motion

Health Stocks in Motion

Biolase is hammered on a delisting notice.

Health Stocks in Motion

Health Stocks in Motion

IntraBiotics is hammered while OraSure soars.

Dodging the Russell 'Boomerangs'

Dodging the Russell 'Boomerangs'

Steer clear of stocks being demoted in the next Russell index rebalancing.

Be Unfazed When News Surprises Come

Trading on news is a game of anticipation and reaction.

Mad Cow Probe Moving Slowly

Mad Cow Probe Moving Slowly

Meanwhile, restaurant shares rebound and more beef-testing and alternative food stocks surge.

Mad Cow News Boosts Biotechs

Mad Cow News Boosts Biotechs

Shares of Bio-Rad Laboratories, Orchid BioSciences and V.I. Technologies surge.

Dow Rally Takes a Holiday

Dow Rally Takes a Holiday

Investors focus on mixed economic reports and mad cow disease in a holiday-shortened session.

Some Skeptics Like the Sound of XM's Story

The radio company is adding subscribers fast and furiously, putting big risk on the short side.

TheStreet Quant Rating: B (Buy)